Cargando…

Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages

Despite the progress that has occurred in recent years in the development of therapies to treat painful and inflammatory diseases, there is still a need for effective and potent analgesics and anti-inflammatory drugs. It has long been known that several types of antioxidants also possess analgesic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Staurengo-Ferrari, Larissa, Badaro-Garcia, Stephanie, Hohmann, Miriam S. N., Manchope, Marília F., Zaninelli, Tiago H., Casagrande, Rubia, Verri, Waldiceu A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337248/
https://www.ncbi.nlm.nih.gov/pubmed/30687097
http://dx.doi.org/10.3389/fphar.2018.01536
_version_ 1783388209222254592
author Staurengo-Ferrari, Larissa
Badaro-Garcia, Stephanie
Hohmann, Miriam S. N.
Manchope, Marília F.
Zaninelli, Tiago H.
Casagrande, Rubia
Verri, Waldiceu A.
author_facet Staurengo-Ferrari, Larissa
Badaro-Garcia, Stephanie
Hohmann, Miriam S. N.
Manchope, Marília F.
Zaninelli, Tiago H.
Casagrande, Rubia
Verri, Waldiceu A.
author_sort Staurengo-Ferrari, Larissa
collection PubMed
description Despite the progress that has occurred in recent years in the development of therapies to treat painful and inflammatory diseases, there is still a need for effective and potent analgesics and anti-inflammatory drugs. It has long been known that several types of antioxidants also possess analgesic and anti-inflammatory properties, indicating a strong relationship between inflammation and oxidative stress. Understanding the underlying mechanisms of action of anti-inflammatory and analgesic drugs, as well as essential targets in disease physiopathology, is essential to the development of novel therapeutic strategies. The Nuclear factor-2 erythroid related factor-2 (Nrf2) is a transcription factor that regulates cellular redox status through endogenous antioxidant systems with simultaneous anti-inflammatory activity. This review summarizes the molecular mechanisms and pharmacological actions screened that link analgesic, anti-inflammatory, natural products, and other therapies to Nrf2 as a regulatory system based on emerging evidences from experimental disease models and new clinical trial data.
format Online
Article
Text
id pubmed-6337248
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63372482019-01-25 Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages Staurengo-Ferrari, Larissa Badaro-Garcia, Stephanie Hohmann, Miriam S. N. Manchope, Marília F. Zaninelli, Tiago H. Casagrande, Rubia Verri, Waldiceu A. Front Pharmacol Pharmacology Despite the progress that has occurred in recent years in the development of therapies to treat painful and inflammatory diseases, there is still a need for effective and potent analgesics and anti-inflammatory drugs. It has long been known that several types of antioxidants also possess analgesic and anti-inflammatory properties, indicating a strong relationship between inflammation and oxidative stress. Understanding the underlying mechanisms of action of anti-inflammatory and analgesic drugs, as well as essential targets in disease physiopathology, is essential to the development of novel therapeutic strategies. The Nuclear factor-2 erythroid related factor-2 (Nrf2) is a transcription factor that regulates cellular redox status through endogenous antioxidant systems with simultaneous anti-inflammatory activity. This review summarizes the molecular mechanisms and pharmacological actions screened that link analgesic, anti-inflammatory, natural products, and other therapies to Nrf2 as a regulatory system based on emerging evidences from experimental disease models and new clinical trial data. Frontiers Media S.A. 2019-01-11 /pmc/articles/PMC6337248/ /pubmed/30687097 http://dx.doi.org/10.3389/fphar.2018.01536 Text en Copyright © 2019 Staurengo-Ferrari, Badaro-Garcia, Hohmann, Manchope, Zaninelli, Casagrande and Verri. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Staurengo-Ferrari, Larissa
Badaro-Garcia, Stephanie
Hohmann, Miriam S. N.
Manchope, Marília F.
Zaninelli, Tiago H.
Casagrande, Rubia
Verri, Waldiceu A.
Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
title Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
title_full Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
title_fullStr Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
title_full_unstemmed Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
title_short Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
title_sort contribution of nrf2 modulation to the mechanism of action of analgesic and anti-inflammatory drugs in pre-clinical and clinical stages
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337248/
https://www.ncbi.nlm.nih.gov/pubmed/30687097
http://dx.doi.org/10.3389/fphar.2018.01536
work_keys_str_mv AT staurengoferrarilarissa contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages
AT badarogarciastephanie contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages
AT hohmannmiriamsn contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages
AT manchopemariliaf contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages
AT zaninellitiagoh contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages
AT casagranderubia contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages
AT verriwaldiceua contributionofnrf2modulationtothemechanismofactionofanalgesicandantiinflammatorydrugsinpreclinicalandclinicalstages